Safety profiles of erlotinib therapy in patients with advanced non-small-cell lung cancer

Research output: Contribution to journalArticle

3 Citations (Scopus)


Erlotinib is an orally available, small-molecule EGF receptor tyrosine kinase inhibitor. It has shown promising activity in chemotherapy-relapsed patients with advanced non-small-cell lung cancer and is now approved in many countries. To date, there have been a number of clinical studies of erlotinib therapy demonstrating its safety as well as its efficacy. This article summarizes clinical study results in advanced non-small-cell lung cancer, so that we can comprehensively understand the toxicities expected with erlotinib in non-small-cell lung cancer patients.

Original languageEnglish
Pages (from-to)993-999
Number of pages7
JournalExpert Review of Anticancer Therapy
Issue number7
Publication statusPublished - Jul 2011



  • elrotinib
  • non-small-cell lung cancer
  • toxicity

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this